Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tests a new drug called SKB264 against standard chemotherapy in about 376 people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy (EGFR-TKI). The goal is to see if SKB264 alone can he…

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This early-phase study tests a new drug called SKB410 in about 54 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any early signs that the drug can control tumor growth. Participants receive mu…

This study tests a new drug (SKB264) alone or with another drug (KL-A167) in people with advanced HER2-negative breast cancer that hasn't been treated yet. The goal is to see if the combination is safe and shrinks tumors. About 175 adults with triple-negative or HR+/HER2- breast …

This early-stage study tests a new drug called A166 in 120 adults with advanced HER2-positive solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participants must h…

This study tests an experimental drug called KL590586 in people with advanced solid tumors that have a specific change in the RET gene. The goal is to see if the drug is safe and can shrink tumors. About 414 adults whose cancer has not responded to standard treatments will take t…

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung or nasopharyngeal cancer) that have not responded to other treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants receive the drug until it stops worki…

This phase 3 trial tests a new drug called SKB264 against standard treatments for people with advanced triple-negative breast cancer that has worsened after at least two prior therapies. The study includes about 254 adults aged 18 to 75. The main goal is to see if SKB264 can dela…

This study tests whether adding the drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18-75 with this type of throat cancer are parti…

This study tests a new drug called SKB264 in 20 women with ovarian cancer that has come back. The goal is to see if the drug shrinks tumors and how the body processes it. Participants receive the drug and are monitored for safety and effectiveness.

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 406 participants who have not had …